Clinical Focus
Business Focus
Spotlight
Subscribe
CE/CME
- CDC
- Heart Failure
- Cardiovascular Clinical Consult
- Adult Immunization
- Hepatic Disease
- Rare Disorders
- Pediatric Immunization
- Implementing The Topcon Ocular Telehealth Platform
- Weight Management
- Screening
- Monkeypox
- Guidelines
- Men's Health
- Psychiatry
- Allergy
- Nutrition
- Women's Health
- Cardiology
- Substance Use
- Pediatrics
- Kidney Disease
- Genetics
- Complimentary & Alternative Medicine
- Dermatology
- Endocrinology
- Oral Medicine
- Otorhinolaryngologic Diseases
- Pain
- Gastrointestinal Disorders
- Geriatrics
- Infection
- Musculoskeletal Disorders
- Obesity
- Rheumatology
- Technology
- Cancer
- Nephrology
- Anemia
- Neurology
- Pulmonology
Social Determinants of Health and Prevention of Cardiovascular Disease
Research demonstrates that socioeconomic inequalities are "strong determinants" of cardiovascular risk throughout the world.
Members of the writing committee for the American College of Cardiology/American Heart Association 2019 Guideline on Primary Prevention of Cardiovascular Disease incorporated throughout the guideline consideration of how social determinants of health may impact the efficacy of specific guidance and prescriptions for an individual patient. ACC/AHA recommends that clinicians revisit these considerations at each follow-up visit.
Considerations include but are not limited to socioeconomic and educational status as well as cultural, home, and employment environments. The slides below highlight examples of considerations cited by the ACC/AHA for 7 health domains.
More than Half of US Adults May Be Eligible for Semaglutide Therapy, Accordng to New Estimates
Millions of US adults could benefit from semaglutide treatment for diabetes, obesity, and/or CV disease but insurance isn't guaranteed and the drug is costly.
Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care
Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.
Investigational Oral Agent Muvalaplin Reduces Lp(a) by Up to 85% in High-Risk Adults: Phase 2 Data
Lp(a) is a genetically-driven and independent risk factor for CVD with no approved treatments. Lilly is advancing muvalaplin and has some good competition.
Obesity & Type 2 Diabetes: An Expert Discussion
In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.
Aprocitentan Now Available in the US for Treatment-Resistant Hypertension
Aprocitentan is the first-and-only dual endothelin receptor antagonist approved for the treatment of systemic hypertension.
GLP-1RAs Cut Early Colorectal Cancer Risk in Adults with T2D: Daily Dose
Your daily dose of the clinical news you may have missed.
More than Half of US Adults May Be Eligible for Semaglutide Therapy, Accordng to New Estimates
Millions of US adults could benefit from semaglutide treatment for diabetes, obesity, and/or CV disease but insurance isn't guaranteed and the drug is costly.
Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care
Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.
Investigational Oral Agent Muvalaplin Reduces Lp(a) by Up to 85% in High-Risk Adults: Phase 2 Data
Lp(a) is a genetically-driven and independent risk factor for CVD with no approved treatments. Lilly is advancing muvalaplin and has some good competition.
Obesity & Type 2 Diabetes: An Expert Discussion
In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.
Aprocitentan Now Available in the US for Treatment-Resistant Hypertension
Aprocitentan is the first-and-only dual endothelin receptor antagonist approved for the treatment of systemic hypertension.
GLP-1RAs Cut Early Colorectal Cancer Risk in Adults with T2D: Daily Dose
Your daily dose of the clinical news you may have missed.